Prenetics Global (NASDAQ:PRE) Trading 3.8% Higher

Shares of Prenetics Global Limited (NASDAQ:PRE) traded up 3.8% during trading on Thursday . The stock traded as high as $5.36 and last traded at $4.97. 188,526 shares were traded during trading, an increase of 77% from the average session volume of 106,356 shares. The stock had previously closed at $4.79.

Analyst Ratings Changes

Separately, Cantor Fitzgerald dropped their target price on shares of Prenetics Global from $10.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, April 4th.

Prenetics Global Price Performance

The business’s 50 day moving average is $4.40 and its 200 day moving average is $4.81. The stock has a market cap of $45.43 million, a price-to-earnings ratio of -1.04 and a beta of -0.11.

Prenetics Global (NASDAQ:PRE) last announced its quarterly earnings results on Monday, April 1st. The company reported ($0.52) earnings per share for the quarter. Prenetics Global had a negative net margin of 193.60% and a negative return on equity of 11.15%. The company had revenue of $5.43 million during the quarter. As a group, analysts forecast that Prenetics Global Limited will post -3.59 earnings per share for the current year.

Institutional Investors Weigh In On Prenetics Global

An institutional investor recently raised its position in Prenetics Global stock. Nomura Holdings Inc. grew its holdings in Prenetics Global Limited (NASDAQ:PRE) by 140.4% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 193,963 shares of the company’s stock after buying an additional 113,288 shares during the period. Nomura Holdings Inc. owned 2.12% of Prenetics Global worth $1,146,000 at the end of the most recent reporting period. 25.01% of the stock is currently owned by institutional investors and hedge funds.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.